Developing a treatment to inhibit tau oligomers for Alzheimer's disease
Official title: GMP Production of a Tau Oligomer Inhibitor to Enable Clinical Development forADRD
Funded at Oligomerix, INC · NIH-10906217 · Data updated 2026-11-12
This study is testing a new pill that aims to help people with Alzheimer's by blocking harmful proteins in the brain, and if you join, you'll help us see how well it works through some simple tests.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oligomerix, INC NIH-funded |
| Lab location | 1 site (White Plains, UNITED STATES) |
| Project start | September 30, 2019 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,497,873 |
| NIH project number | 5R44AG066384-04 |
| Project ID | NIH-10906217 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related dementias who meet specific eligibility criteria for the clinical trials.
✕Less likely to help
Patients with other forms of dementia not related to Alzheimer's disease may not benefit from this research.
What this research studies
This research focuses on creating a new oral medication that inhibits tau oligomers, which are linked to Alzheimer's disease and related dementias. The project has completed preclinical testing and is preparing for human trials to evaluate the treatment's effectiveness. Patients will participate in a double-blind study to assess changes in specific biomarkers in their blood and cerebrospinal fluid. The goal is to provide a disease-modifying therapy that can be easily administered and has the potential to significantly impact the lives of those affected by Alzheimer's disease.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that slows the progression of Alzheimer's disease, improving quality of life for patients and reducing healthcare costs.
How similar studies have gone: Previous research has shown promise in targeting tau oligomers, indicating potential for success with this approach.
Where this research is happening
-
Oligomerix, INC
White Plains, United States Active
Researchers
- Principal investigator: Moe, James G. — Oligomerix, INC
- Study coordinator: Moe, James G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.